2026-01-17 - Analysis Report
**Company Overview:** Philip Morris International Inc is a multinational tobacco conglomerate.

**Comparative Analysis**

* Review Stock (PM): Cumulative Return = 100.09%
* Comparison Stock (VOO): Cumulative Return = 93.36%
* Divergence = -6.73% (difference in cumulative return on the last day of the data)
* Relative Divergence: 59.90% (current position when the minimum-maximum fluctuation range is set to 100)

**Alpha, Beta, and Market Capitalization Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | -14.0% | 21.7% | -18.0% | 0.5 | 103.9B |
| 2017-2019  | 18.0% | 21.7% | 1.0% | 0.5 | 132.4B |
| 2018-2020  | 5.0% | 21.7% | -15.0% | 0.8 | 128.9B |
| 2019-2021  | 29.0% | 19.5% | -14.0% | 0.8 | 147.9B |
| 2020-2022  | 18.0% | 19.5% | 20.0% | 0.7 | 157.6B |
| 2021-2023  | 11.0% | 17.1% | 10.0% | 0.5 | 146.4B |
| 2022-2024  | 11.0% | 17.1% | -9.0% | 0.4 | 187.3B |
| 2023-2025  | 50.0% | 16.7% | -12.0% | 0.2 | 249.7B |

**Price Fluctuation Analysis**

* Close Price: $173.62
* Last-Market Price: $173.62 (with a change of +0.61)
* 5-day Moving Average (SMA): $169.65
* 20-day SMA: $162.20
* 60-day SMA: $156.04

**RSI, PPO, and Delta Analysis**

* Market Risk Indicator (MRI): 0.80 (Medium Investment)
* RSI: 74.02
* PPO: 0.83
* Recent Relative Divergence Change: 22.00 (+)
* 7-day Rank Change: 0 (0)
* 7-day Dynamic Expected Return Change: 0.00 (0)
* Sharp Rebound/Decline Indicator: Sharp Rebound
* Expected Return (Percentage): -7.10%

**Recent News and Significant Events**

* Philip Morris (PM) Stock Gains on Strong U.S. Investment and Positive Outlook
* Philip Morris International (PM) Invests Over $20B in U.S., Stock Rises for Seven Consecutive Days
* Philip Morris International Inc. $PM Stock Holdings Increased by Retirement Planning Group LLC
* What Philip Morris International (PM)'s Smoke-Free Pivot and Dividend Move Means For Shareholders
* Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead

**Analyst Opinions**

* Analyst Consensus: Buy
* Mean Rating: 1.72 (~Buy)
* Opinions: 16
* Target Price (avg/high/low): 182.88 / 220.00 / 158.00

**Quarterly Earnings Analysis**

| Date | EPS | Revenue |
|-----|-----|---------|
| 2025-10-24 | 2.23 | 10.85B$ |
| 2025-07-25 | 1.95 | 10.14B$ |
| 2025-04-24 | 1.72 | 9.30B$ |
| 2024-10-24 | 1.98 | 9.91B$ |
| 2025-10-24 | 1.98 | 9.91B$ |

**Revenue and Profitability Analysis**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $10.85B | 67.85% |
| 2025-06-30 | $10.14B | 67.66% |
| 2025-03-31 | $9.30B | 67.32% |
| 2024-12-31 | $9.71B | 64.73% |
| 2024-09-30 | $9.91B | 66.04% |

**Capital and Profitability Analysis**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $-10.91B | -31.87% |
| 2025-06-30 | $-11.97B | -25.40% |
| 2025-03-31 | $-10.90B | -24.68% |
| 2024-12-31 | $-11.75B | 4.93% |
| 2024-09-30 | $-9.69B | -31.79% |

**Comprehensive Analysis**

Philip Morris International Inc has shown a cumulative return of 100.09% compared to the S&P 500's 93.36%. The company's recent stock price fluctuations indicate a sharp rebound, with a 5-day moving average of $169.65 and a 20-day SMA of $162.20. The RSI and PPO indicators show a relatively stable position, with an RSI of 74.02 and a PPO of 0.83. The analyst consensus is to buy the stock, with a target price of $182.88. The quarterly earnings analysis shows a steady increase in revenue, with an average revenue of $10.15B. The financial information indicates a relatively stable profit margin, with an average profit margin of 66.52% and an average ROE of -24.88%.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.